A Study of Orforglipron (LY3502970) in Chinese Participants With Obesity or Overweight and Weight-Related Health Problems (ATTAIN-CN)

August 25, 2026 updated by: Eli Lilly and Company

A Phase 3, Randomized, Double-Blind Study to Investigate the Efficacy and Safety of Once- Daily Oral Orforglipron Compared With Placebo in Chinese Adult Participants With Obesity or Overweight With Weight-Related Comorbidities

The purpose of this study is to learn how well orforglipron works and how safe it is in Chinese adults with obesity or overweight and related health problems. Participation in this study will last about 53 weeks (about 1 year).

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

192

Phase

  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

  • Name: Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
  • Phone Number: 1-317-615-4559
  • Email: LillyTrials@Lilly.com

Study Contact Backup

Study Locations

  • China
      • Chengdu, China, 610072
        • Sichuan Provincial People's Hospital
        • Principal Investigator:
          • Limin Tian
      • Guangzhou, China, 510280
        • Zhujiang Hospital
        • Principal Investigator:
          • Jia Sun
      • Hangzhou, China, 310014
        • Zhejiang Provincial People's Hospital
        • Principal Investigator:
          • Xiaohong Wu
      • Hangzhou, China, 310003
        • The First Affiliated Hospital, Zhejiang University School of Medicine
        • Principal Investigator:
          • Xiaomu Li
      • Harbin, China, 150001
        • The Fourth Affiliated Hospital of Harbin Medical University
        • Contact:
          • Phone Number: 18903602198
        • Principal Investigator:
          • ZhiFeng Cheng
      • Hefei, China, 230011
        • The Second People's Hospital of Hefei
        • Principal Investigator:
          • Yonghong Cao
      • Jinan, China, 250013
        • Jinan Central Hospital
        • Principal Investigator:
          • Nianrong Mi
      • Luoyang Shi, China, 471003
        • The First Affiliated Hospital of Henan University of Science &Technology
        • Principal Investigator:
          • Hongwei Jiang
        • Contact:
          • Phone Number: 13653880139
      • Nanchang, China, 330006
        • Jiangxi Provincial People's Hospital
        • Principal Investigator:
          • Zongyou Cheng
        • Contact:
          • Phone Number: 13767035719
      • Nanjing, China, 210029
        • Jiangsu Province Hospital
        • Principal Investigator:
          • Yun Liu
        • Contact:
          • Phone Number: 18805152008
      • Nanjing, China, 210006
        • Nanjing First Hospital
        • Principal Investigator:
          • Qian Li
      • Nanjing, China, 210011
        • The Second Affiliated Hospital of Nanjing Medical University
        • Principal Investigator:
          • Yibing Lu
        • Contact:
          • Phone Number: 18951762960
      • Shanghai, China
        • Shanghai Sixth People's Hospital
        • Principal Investigator:
          • Jian Zhou

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Have body mass index (BMI) ≥28.0 kilograms per square meter (kg/m2) and <30 kg/m2 or ≥24.0 kg/m2 and <28 kg/m2, and at least 1 of the following weight-related comorbidities at screening:

    • hypertension
    • dyslipidemia
    • obstructive sleep apnea
    • Fatty liver
    • cardiovascular disease
  • Have a history of at least 1 self-reported unsuccessful dietary effort to lose body weight

Exclusion Criteria:

  • Have type 1 diabetes (T1D), type 2 diabetes (T2D), or any other types of diabetes, history of ketoacidosis, or hyperosmolar state/coma
  • Have a self-reported change in body weight >5 kg within 90 days prior to screening
  • Had chronic or acute pancreatitis any time prior to screening
  • Have family (first-degree relative) or personal history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN2) syndrome

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Placebo Comparator: Placebo
Participants will receive placebo orally.
Drug: Placebo
Administered orally.
Experimental: Orforglipron
Participants will receive orforglipron orally.
Drug: Orforglipron
Administered orally.
Other Names:
  • LY3502970

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Mean Percent Change From Baseline in Body Weight
Time Frame: Baseline, Week 48
Baseline, Week 48

Secondary Outcome Measures

Outcome Measure
Time Frame
Mean Change from Baseline in Waist Circumference
Time Frame: Baseline, Week 48
Baseline, Week 48
Mean Change from Baseline in Body Mass Index (BMI)
Time Frame: Baseline, Week 48
Baseline, Week 48
Mean Change from Baseline in Hemoglobin A1c (HbA1c)
Time Frame: Baseline, Week 48
Baseline, Week 48
Mean Change from Baseline in Fasting Glucose
Time Frame: Baseline, Week 48
Baseline, Week 48
Mean Percent Change from Baseline in Fasting Insulin
Time Frame: Baseline, Week 48
Baseline, Week 48
Mean Change from Baseline in Systolic Blood Pressure (SBP)
Time Frame: Baseline, Week 48
Baseline, Week 48
Mean Change from Baseline in Diastolic Blood Pressure (DBP)
Time Frame: Baseline, Week 48
Baseline, Week 48
Mean Percent Change from Baseline in Fasting non-HDL Cholesterol
Time Frame: Baseline, Week 48
Baseline, Week 48
Mean Percent Change from Baseline in Fasting Triglycerides
Time Frame: Baseline, Week 48
Baseline, Week 48
Mean Change from Baseline in Short Form Version 2 (SF-36v2) Acute Form Domain Scores
Time Frame: Baseline, Week 48
Baseline, Week 48

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Eli Lilly and Company

Investigators

  • Study Director: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST), Eli Lilly and Company

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

December 1, 2026

Primary Completion (Estimated)

March 1, 2028

Study Completion (Estimated)

March 1, 2028

Study Registration Dates

First Submitted

August 25, 2026

First Submitted That Met QC Criteria

August 25, 2026

First Posted (Actual)

August 27, 2026

Study Record Updates

Last Update Posted (Actual)

August 27, 2026

Last Update Submitted That Met QC Criteria

August 25, 2026

Last Verified

August 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 27942
  • J2A-GH-GZVC (Other Identifier: Eli Lilly and Company)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

IPD Sharing Time Frame

Data are available 6 months after the primary publication or approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.

IPD Sharing Access Criteria

A research proposal should be approved by an independent review panel and researchers should sign a data sharing agreement.

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL
  • SAP
  • CSR

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

Yes

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe